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Small molecule-mediated 
tribbles homolog 3 promotes 
bone formation induced by bone 
morphogenetic protein-2
Jiabing Fan1, Joan Pi-Anfruns2, Mian Guo3, Dan C. S. Im1, Zhong-Kai Cui  1, Soyon Kim4, 
Benjamin M. Wu1,4, Tara L. Aghaloo2 & Min Lee1,4
Although bone morphogenetic protein-2 (BMP2) has demonstrated extraordinary potential in bone 
formation, its clinical applications require supraphysiological milligram-level doses that increase 
postoperative inflammation and inappropriate adipogenesis, resulting in well-documented life-
threatening cervical swelling and cyst-like bone formation. Recent promising alternative biomolecular 
strategies are toward promoting pro-osteogenic activity of BMP2 while simultaneously suppressing its 
adverse effects. Here, we demonstrated that small molecular phenamil synergized osteogenesis and 
bone formation with BMP2 in a rat critical size mandibular defect model. Moreover, we successfully 
elicited the BMP2 adverse outcomes (i.e. adipogenesis and inflammation) in the mandibular defect 
by applying high dose BMP2. Phenamil treatment significantly improves the quality of newly formed 
bone by inhibiting BMP2 induced fatty cyst-like structure and inflammatory soft-tissue swelling. The 
observed positive phenamil effects were associated with upregulation of tribbles homolog 3 (Trib3) 
that suppressed adipogenic differentiation and inflammatory responses by negatively regulating 
PPARγ and NF-κB transcriptional activities. Thus, use of BMP2 along with phenamil stimulation or 
Trib3 augmentation may be a promising strategy to improve clinical efficacy and safety of current BMP 
therapeutics.
Mandibular bone defects are commonly caused by traumatic injury, infection, congenital deformity, and sec-
ondary treatment of varying pathologies such as tumor resection and drug-induced osteonecrosis, leading to 
undesirable effects on oral function and appearance1. Microvascular free tissue transfer is the preferred approach 
in current mandibular reconstruction, however, it raises the concern of donor site morbidities and periopera-
tive complications2, 3. Tissue engineering approach with osteoinductive growth factors is a promising alternative 
option for the reconstruction of bony defects especially with large mandibular defects4, 5.
Bone morphogenetic protein 2 (BMP2) is believed to be the most potent osteoinductive factor available and 
has been extensively studied for the treatment of many bone fractures and bone defects6, 7. However, the clinical 
application of BMP2 requires supraphysiological milligram-level doses that may increase inappropriate adipo-
genesis and cyst-like hollow bone formation8, 9. Furthermore, the premature release of such high dose BMP2 from 
conventional collagen carriers may lead to numerous side effects such as ectopic bone formation, inflammatory 
soft tissue swelling, or osteoclastic bone resorption10–12. Herein, it is necessary to develop an alternative molecular 
therapeutic approach capable of complementing BMP2 activity to maximized biological efficiency while simulta-
neously minimizing BMP2-associated adverse effects.
Small molecule phenamil, an amiloride derivative, was shown to effectively invoke the osteogenesis of mes-
enchymal progenitor cell as well as the enhancement of bone repair in in vitro and in vivo studies13–15. Moreover, 
our recent studies demonstrated phenamil synergized osteogenesis and bone formation with BMP2 by enhancing 
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BMP/Smad signaling15, 16. The increased BMP signaling by phenamil is thought to be through the induction of 
tribbles homolog 3 (Trib3) that degrades Smad ubiquitin regulatory factor 1 (Smurf1), a negative regulator of 
BMP receptor-regulated Smads13, 15, 17. Moreover, recent studies suggest that Trib3 suppresses the expression of 
peroxisome proliferator activated receptor gamma (PPARγ), a master regulator of adipogenesis, and serves as a 
negative regulator of pro-inflammatory cytokines18–22. Thus, phenamil treatment has high potential to effectively 
complement the BMP activity to maximize osteogenesis without exogenous application of supraphysiological 
BMP doses while inhibiting BMP-induced adverse outcomes (i.e. adipogenesis and inflammation).
Here, we investigated whether phenamil can improve the amount and quality of newly formed bone induced 
by BMP2. First in this study, we will determine if phenamil can maximize BMP2 induced bone formation in 
critical-sized large mandibular bone defects created in rats. Next, we will apply high dose BMP2 to induce adverse 
cyst-like bone formation and inflammation in the mandibular defect model and will test whether phenamil can 
inhibit BMP2 induced fatty cyst-like structure and inflammatory soft-tissue swelling. Lastly, we will determine 
whether the positive phenamil effects in the combinatorial treatment of phenamil + BMP2 are through increased 
Trb3 expression in vitro cell culture and in vivo early mandibular implantation.
Results
Phenamil synergizes bone formation with BMP2 and inhibits BMP2 induced cyst-like bone for-
mation. Various concentrations of BMP2 (5–75 µg in 50 µl defect volume, 100–1500 µg/ml) were loaded onto 
apatite-coated PLGA scaffolds and implanted into mandibular defects. MicroCT analysis demonstrated enhanced 
new bone formation with increasing BMP-2 dose at 8 weeks post-surgery (Fig. 1a and c). Although BMP2 at 
30 µg or higher was able to fuse the defects, it also consistently induced hollow cysts and sparse trabecular bone 
as observed by sagittal microCT (Fig. 1b). The quantitative analysis demonstrated that bone volume was not sig-
nificantly different among the experimental groups, but trabecular bone number was significantly reduced with 
increasing BMP-2 dose (Fig. 1d and e). The cystic structure induced by BMP2 at 30 µg or higher presented low 
osseous matrix production filled with fatty marrow as observed by H&E, Masson’s trichrome, osteocalcin (OCN) 
and PicroSirius red stain (Fig. 1f–h and Supplementary Fig. 1a). Instead, the extensive expression of adipogenic 
regulator PPARγ was detected in the bone cysts (Fig. 1i). Moreover, intense TRAP stain was detected in high dose 
BMP2 treatment over 50 µg, indicating strong osteoclastic bone resorption (Supplementary Fig. 1b).
Next, we investigated efficacy of phenamil to improve BMP2 induced bone formation. Combined treatment 
with phenamil and BMP2 induced almost complete mandibular bone healing even at very low BMP2 dose (5 µg) 
(Fig. 2a and c). The combined treatment significantly increased both bone volume and trabecular bone number 
compared with BMP2 alone group (Fig. 2d and e). Moreover, co-treatment with phenamil + BMP2 resulted in 
dense trabecular structure without cyst formation at all tested BMP2 doses (Fig. 2b). Histological and immu-
nohistochemical analysis demonstrated conspicuous ossification in all combinatorial treatments (Fig. 2f–h and 
Supplementary Fig. 2a). In contrast to BMP2 alone groups, minimal expression of PPARγ was observed in phe-
namil + BMP2 groups (Fig. 2i) with low TRAP positive stain (Supplementary Fig. 2b).
Phenamil inhibits BMP2-induced inflammatory soft tissue swelling and adipogenesis. We fur-
ther explored the effect of phenamil on BMP2-induced complication in the mandibular defect as early as 7 days 
postoperatively. Gross and histological observation revealed high tissue swelling in the defect treated with high 
dose BMP2 (30 μg) (Fig. 3a and b). Quantitative measurement showed that tissue weight and volume were ~8.4- 
and ~4.5- folds higher in high dose BMP2 groups, respectively, than that of low dose BMP2 (5 μg) groups (Fig. 3c 
and d). In contrast, high-dose BMP2 groups co-treated with phenamil exhibited no discernable swelling with 
lower tissue weight and volume (Fig. 3a–d). Moreover, a massive infiltration of cells that positively stain CD68, 
a macrophage marker, were observed in the implant containing high dose BMP2, but macrophage aggregation 
was significantly decreased in phenamil + BMP2 groups (Fig. 3e and f). Histological and immunohistochemical 
analysis showed no apparent neo-bone formation detected in all treated groups by histological analysis (Fig. 4a), 
while the expression of Runx2 and OCN was significantly increased in phenamil + BMP2 treatment (Fig. 4b and 
c). Strong staining for PPARγ was detected in high dose BMP2 groups, while the low level of PPARγ expression 
was observed in phenamil-treated groups with or without BMP2 (Fig. 4d). The expression of phosphorylated p65, 
a marker of NF-κB activation that regulates inflammatory response, was significantly increased only in implants 
treated with high-dose BMP2 alone (Fig. 4e). Strong staining for Trib3 was detected in phenamil containing 
groups, but not in BMP-2 alone groups (Fig. 4f).
Phenamil inhibits BMP2-induced inflammation in vitro. To investigate whether phenamil can inhibit 
BMP2-induced inflammation in vitro, RAW264.7 cells (a macrophage cell line) were treated with BMP2 at 
500 ng/mL in the presence or absence of phenamil. The results demonstrated that BMP2 stimulation significantly 
increases expression of IL-1α and IL-6 compared with control (Fig. 5a). Addition of phenamil reversed their 
expression to the level comparable with control (Fig. 5a). Consistently, ELISA assay indicated that phenamil 
treatment suppressed the secretion of inflammatory cytokines (IL-1α and IL-6) in the presence or absence of 
BMP2 (Fig. 5b). The observed decrease in inflammatory reaction was accompanied by upregulation of Trib3 
(Fig. 5a). The similar anti-inflammatory effects of phenamil were confirmed in the NIH3T3 fibroblast and 
C2C12 myoblast cell lines (Supplementary Fig. 3a and b). Since the expression of inflammatory cytokines may 
depend on NF-κB activity, we further monitor the activity of NF-κB signaling pathway in RAW264.7 by lucif-
erase NF-κB reporter assay. The assay measured significant increase in NF-κB transcription activity by BMP2. 
In contrast, the BMP-driven promoter activity was decreased after phenamil treatment (Fig. 5c). Moreover, 
western-blot assay demonstrated that phenamil impedes BMP2-induced phosphorylation of p65 and this was 
accompanied by elevation of Trib3 level (Fig. 5d, Supplementary Fig. 6). We further investigated the effects of 
phenamil-mediated anti-inflammation in BMP2 induced osteogenesis by co-culturing BMSCs with RAW 264.7 
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cells with phenamil (20 μM) ± BMP2 (500 ng/mL). ALP expression of BMSCs induced by BMP2 was significantly 
reduced by co-culture with RAW 264.7 cells (Fig. 5e and f). In contrast, RAW 264.7 cells did not change the level 
of ALP expression in BMSCs in the presence of phenamil (Fig. 5e and f).
Knockdown of Trb3 attenuates pro-osteogenic and anti-adipogenic activities of phenamil in 
vitro. We investigated the role of Trib3 in phenamil + BMP2 mediated mesenchymal stem cell differentiation 
in vitro. hBMSCs were transduced with Trib3 siRNA or control siRNA and treated with phenamil (20 μM) and/
Figure 1. BMP2 dose ranging from 0 to 75 μg (0–1.5 mg/mL) was used to induce cyst-like void bone formation 
with a dose-dependent fashion in the rat critical-sized (5 × 5 mm) mandibular defect. 8 weeks postoperatively, 
the collected mandibular implants were measured by the following analysis: Micro-computed tomography 
(microCT) images in general (a) and sagittal sections (b); Quantification of % bone surface area (c), bone 
volume (mm3) (d), and trabecular number (Tb.N, mm−1) (e); Histological analysis including HE staining (scale 
bar = 500 µm) (f), Masson’s trichrome staining (scale bar = 500 µm) (g), and immunohistochemical staining for 
OCN (scale bar = 50 µm) (h) and PPARγ (scale bar = 50 µm) (i). Red arrowhead indicates high expression of 
PPARγ. Blank, blank scaffold; BMP, BMP2; NS, no significant difference. Data presented as means ± SD (n = 3/
group); *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
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Figure 2. The extra use of phenamil at 600 µM (total 12 μg per defect) impedes high dose BMP2-induced cyst-
like void bone formation replaced with new robust ossification formation. 8 weeks postoperatively, the collected 
implants were measured by the following analysis: Micro-computed tomography (microCT) images in general 
(a) and sagittal sections (b); Quantification of % bone surface area (c), bone volume (mm3) (d), and trabecular 
number (Tb.N, mm−1) (e); Histological analysis including HE staining (scale bar = 500 µm) (f), Masson’s 
trichrome staining (scale bar = 500 µm) (g), and immunohistochemical staining for OCN (scale bar = 50 µm) 
(h) and PPARγ (scale bar = 50 µm) (i). Red arrowhead indicates high expression of OCN. Blank, blank scaffold; 
BMP, BMP2; Phe, phenamil. Data presented as means ± SD (n = 3/group); *p < 0.05.
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or BMP2 (100 ng/mL). Treatment of hBMSCs with phenamil significantly increased ALP activity and minerali-
zation induced by BMP2 (Fig. 6a–d). In contrast, knockdown of Trib3 significantly reduced phenamil-induced 
osteogenic differentiation of hBMSCs in the presence or absence of BMP2 (Fig. 6a–d). Phenamil was shown 
to upregulate Trib3 expression and osteogenic differentiation markers including Runx2, ALP and OCN in the 
presence or absence of BMP2, but knockdown of Trb3 significantly reduced the expression of osteogenic gene 
markers induced by phenamil ± BMP2 (Supplementary Fig. 4a–d). Phenamil-induced Trib3 expression was fur-
ther confirmed by western blot and the increased Trib3 downregulated Smurf1, a negative regulator of Smads, 
and thereby enhanced levels of Smads (Supplementary Figs 4e and 6). By contrast, Trib3 knockdown suppressed 
phenamil-induced BMP/Smad signaling (Supplementary Figs 4e and 6).
We further investigated whether phenamil can inhibit BMP2 induced adipogenic differentiation. BMP2 treat-
ment (300 ng/mL) increased lipid accumulation in hBMSC, while the addition of phenamil (10 μM) significantly 
reduced BMP2 induced adipogenesis as observed by Adipored assay (Fig. 6e) and Oil Red O staining (Fig. 6f). 
In contrast, knockdown of Trib3 abrogated the observed effects of phenamil to inhibit adipogenesis. Phenamil 
upregulated Trib3 expression and suppressed expression of adipogenic regulatory genes PPARγ and LPL induced 
by BMP2, while knockdown of Trib3 reversed the anti-adipogenic effect of phenamil (Fig. 6h and Supplementary 
Fig. 5a,b). Phenamil inhibition of PPARγ activity was further confirmed by western blot and the inhibitory effect 
Figure 3. High dose BMP2-induced inflammation/tissue swelling observed in the rat critical-sized mandibular 
defect as early as 7 days postoperatively was suppressed by the additional treatment of phenamil (600 µM, 
total 12 μg per defect). Harvested tissue samples from mandibular defect immediately detected by gross image 
(a) and further analyzed with HE staining at low magnification (scale bar = 1.6 mm) (b), and also measured 
by tissue volume (c) and tissue weight (d), respectively; CD68 expression (representing the presence of 
macrophage cells) with immunofluorescence staining (scale bar = 200 µm) (e) and semi-quantification (f). 
Blank, blank scaffold; L BMP, low dose BMP2 at 5 µg; H BMP, high dose BMP2 at 30 µg; Phe, phenamil at 
600 µM. Data presented as means ± SD (n = 3/group); *p < 0.05.
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was accompanied by enhanced Trib3 level (Fig. 6g and Supplementary Fig. 6). In contrast, Trib3 knockdown 
reversed the phenamil-mediated PPARγ suppression (Fig. 6g).
Discussion
Food and Drug Administration (FDA)-approved BMP2 has demonstrated extraordinary potential in bone for-
mation and is widely used in skeletal repair including spinal fusion, tibial fracture repair, and alveolar ridge/
maxillary sinus augmentation, however its supraphysiological dose requirement has revealed numerous adverse 
outcomes, such as excessive osteoclastogenesis with vertebral osteolysis and life-threating inflammatory cervical 
swelling23–26. In addition, high BMP dose increases PPARγ activity and adipogenesis, resulting in cyst-like void 
bone formation8, 9. Previous reports and our recent study demonstrated that small molecular phenamil synergis-
tically induced osteogenesis and bone formation with BMP2 through upregulation of Trib3, a positive regulator 
of BMP signaling, while lowering BMP2 dose requirement without compromising osteogenic efficacy13, 15, 16.
Tribbles homologs family members (Trib) exert diverse roles in development, cellular differentiation, and 
inflammation18. Among Trib isoforms, Trib3 has been most extensively studied21, 22, 27 and recent study indi-
cates its critical role in modulating BMP pathway by binding to Smurf113, 17. In response to BMP stimulation, 
Trib3 is dissociated from BMP receptor and degrades Smurf1, stabilizing Smads and potentiating BMP signa-
ling17. Downregulation of Trib3 inhibited BMP-mediated osteogenic differentiation of mesenchymal stem cells 
(MSCs). In addition to its critical role in osteogenic differentiation, recent studies also indicate that Trib3 regu-
lates adipogenesis and inflammation by interacting with numerous transcription factors such as PPARγ, CCAAT/
enhancer-binding protein beta (C/EBPB), and NF-κB19–22. Therefore, Trib3 may be a promising molecular target 
to enhance BMP2 induced osteogenesis and reduce adverse effects.
In this study, we increased Trib3 expression using phenamil, a small molecule inducer of Trib3, and eval-
uated the synergistic ability of phenamil with BMP2 to promote bone regeneration in large mandibular dis-
continuity defects. Phenamil has been shown to stimulate BMP signaling and osteogenesis by upregulating 
Trib3 expression in our previous in vitro and in vivo studies15. Our data showed that the addition of phenamil to 
BMP-2-treated defects significantly increased bone regeneration over defects treated with BMP-2 alone, and the 
observed increase in bone healing by phenamil was induced through Trib3 upregulation in the defects. While 
Figure 4. Phenamil-inhibited high dose BMP2-induced inflammation/tissue swelling was analyzed by 
histological and immunohistochemical analysis. HE staining at high magnification (a); Immunohistochemical 
staining for the detection of Runx2 (b), OCN (c), PPARγ (d) phosphorylated p65 (e), and Trib3 (f). Scale 
bar = 50 µm. Blank, blank scaffold; L BMP, low dose BMP2 at 5 µg; H BMP, high dose BMP2 at 30 µg; Phe, 
phenamil at 600 µM (total 12 µg per defect); p-p65, phosphorylated-p65.
www.nature.com/scientificreports/
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the molecular mechanism is not fully understood, the amiloride analog phenamil is known to inhibit ion chan-
nel function in cells, which could be critical for Trib3 induction. Previous study demonstrated that phenamil 
increased Trib3 transcriptional activity via activation of the calcium-calcineurin-unclear factor of activated T cell 
(NFAT) pathway and this was mediated by inhibition of acid-sensing ion channels (ASICs)28.
Figure 5. In vitro analysis of the effects of phenamil treatment on high doses BMP2-induced inflammation 
in RAW264.7 cells. (a) Increased inflammatory genes (IL-1α and IL-6) in BMP2 (500 ng/mL) treatment were 
suppressed by extra phenamil treatment (20 µM) via the increase of Trib3. The level of gene expression was 
measured by real-time PCR assay; (b) Elisa assay was utilized to detect inflammatory cytokines expression 
(IL-1α and IL-6); (c) NF-κB activities was examined by luciferase assay; (d) Western-blot assay confirmed 
phenamil-mediated inflammatory prohibition by increased Trib3 expression to suppress phosphorylated p65 
(NF-κB signaling); (e,f) A co-culture system between RAW264.7 and BMSCs showed that phenamil rescued 
the high-dose BMP2-mediated inhibitory osteogenesis by ALP staining (e) and semi-quantification (f). 
Scale bar = 200 µm. Ctr, Control; Phe, phenamil; BMP, BMP2; p-p65, phosphorylated-p65. Data presented as 
means ± SD (n = 3/group); *p < 0.05, **p < 0.01.Uncropped western blot gels are displayed in Supplementary 
Figure 6.
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Since BMP2 adverse outcomes are dose-dependent, we applied various concentrations of BMP2 up to human 
dose equivalent BMP2 (75 µg per defect, 1.5 mg/ml) in our rodent mandibular defect model to elicit adverse 
outcomes associated with high dose BMP2 such as adipogenic differentiation with cyst-like bone formation. 
Although new bone formation was accelerated with increasing BMP2 dose, BMP2 at 30 µg (600 µg/ml) or 
higher consistently induced hollow cysts filled with fatty marrow and distinct PPARγ. Similar observation of 
Figure 6. The role of Trib3 induced by phenamil in the BMP2-mediated osteogenesis and pro-adipogenesis by 
examining Trib3 knockdown hBMSCs. (a–d) Blocking Trib3 expression led to the loss of synergistic effect of 
phenamil (20 µM) on BMP2 (100 ng/mL)-based osteogenesis by the detection of ALP staining/activity (scale 
bar = 200 µm) (a,b), and Alizarin red S staining/quantification (scale bar = 100 µm) (c,d); (e,f) Down-regulated 
Trib3 attenuated the anti-adipogenic capacity of phenamil (10 µM) on high dose BMP2 (300 ng/mL)-induced 
adipogenesis via Adipored assay at day 7 (e) and Oil red staining (scale bar = 100 µm) at day 14 (f); (g) Phenamil 
exerted anti-adipogenesis via up-regulating Trb3 that inhibited PPARγ expression. (h) Trib3 knockdown 
attenuated phenamil (10 μM)-mediated inhibitory BMP2 (300 ng/mL)-induced adipogenic genes: PPARγ in 
hBMSCs. Phe, phenamil; BMP, BMP2; OM, osteogenic medium; AD, adipogenic medium. Data presented as 
means ± SD (n = 3/group); *p < 0.05. Uncropped western blot gels are displayed in Supplementary Figure 6.
www.nature.com/scientificreports/
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BMP2-induced structurally abnormal bone has been reported in a rat long bone defect model29. In contrast, 
co-treatment with phenamil + BMP2 resulted in dense trabecular structure without cyst formation. We also con-
firmed strong expression of Trib3 in phenamil-treated groups. Since phenamil dose-dependently increased oste-
ogenic differentiation in MSCs up to 10–20 μM and bone formation up to 300–600 μM in our previous study15, 
a similar concentration of phenamil at 20 μM and 600 μM was tested in the present in vitro and in vivo studies 
respectively. However, the obtained results may not predict the most optimal phenamil dose and additional stud-
ies will be required to investigate the dose-dependent effect of phenamil.
Cervical swelling is the well-documented severe inflammatory complication associated with BMP229, 30. The 
elevated levels of pro-inflammatory cytokines were detected in seroma in posterior cervical fusion after BMP2 
treatment30–32. Excessive local inflammation is well known to delay bone regeneration processes33, 34. Gross 
observation of the mandible in high BMP2 at day 7 revealed high tissue swelling with a massive infiltration of 
inflammatory cells and p65 positive cells, indicating a strong inflammatory response and NF-κB activation. The 
observed BMP2 induced inflammation was significantly suppressed by phenamil treatment and this was accom-
panied by upregulation of Trib3.
We further investigated the role of Trib3 in phenamil + BMP2 induced inflammation and mesenchymal 
cell differentiation in vitro by culturing RAW264.7 macrophage cells and BMSCs with BMP-2 in the presence 
of absence of phenamil. When cultured with high dose BMP2, RAW 264.7 cells increased NF-κB transcrip-
tion activity and cytokine expression, which were significantly suppressed with phenamil treatment. This 
anti-inflammatory effect of phenamil was accompanied by upregulation of Trib3. Trib3 was well documented 
to be a negative regulator of NF-κB signaling that closely correlates with inflammatory response and immune 
response33–35. Furthermore, osteogenic differentiation of BMSCs induced by BMP2 was significantly reduced 
by co-culturing RAW264.7 cells but their osteogenic phenotype was rescued with the additional of phenamil, 
indicating the positive effect of phenamil-inhibited inflammatory cytokine secretion on osteogenesis. Increasing 
evidences demonstrated that over-activation of NF-κB by inflammatory cytokine such as IL-1 and TNF-α may 
impair the osteogenic differentiation of progenitor cells and bone formation33, 34. The similar inhibitory effect 
of inflammation was reported in mesenchymal precursor cells treated with BMP-2 and the observed inhibitory 
effect was reversed by a blocking of IL-6 expression or NF-κB signaling36, 37. Further study of using specific inhib-
itors will be needed to determine whether the adverse high-dose BMP effects or the positive phenamil effects are 
dependent on inflammatory activities with the co-culture system.
Additionally, the balance of osteogenesis and adipogenesis is crucial in bone remolding during bone homeo-
stasis38. Growing evidences suggested that shifting of MSCs differentiation toward adipogenesis is associated with 
fatty marrow accretion closely linked to age-related bone disorder like osteoporosis39. In the regimen of bone 
tissue engineering, high dose BMP2 required for clinical bone repair may increase PPARγ activity and adipogen-
esis resulting in undesired cyst-like bone formation filled with lipid28. Our in vitro results showed that phenamil 
significantly reduced BMP2 induced adipogenesis of MSCs. This effect was confirmed by expression of PPARγ 
and was mediated by upregulating Trib3. In contrast, knockdown of Trb3 abrogated the observed effects of phe-
namil to inhibit adipogenesis, suggesting that the anti-adipogenic effect of phenamil may be via Trib3 activation. 
Taken together, our complementary strategy of BMP2 treatment along with phenamil-mediated Trib3 expression 
could improve the efficacy and safety of BMP2 in new bone formation by enhancing BMP2 induced osteogenesis 
and reducing adverse BMP2 outcomes. The additional knowledge gained from this study may suggest therapeutic 
strategies that favor osteoblastogenesis over adipogenesis for improved skeletal regeneration and prevention of 
osteoporotic fractures.
Conclusions
Our study demonstrated that phenamil effectively enhanced BMP2 induced osteogenesis and prevented clinically 
relevant adverse effects associated with BMP2 therapy such as adipogenesis and inflammation in a rat mandibular 
defect model. This was accompanied by upregulation of Trib3 and replicated finding in mesenchymal cell culture 
was reversed after knockdown of Trib3, suggesting important roles of Trib3 in phenamil + BMP2 induced osteo-
genesis. Thus, augmentation of Trib3 expression may be a promising therapeutic strategy to improve the quality 
of BMP2 induced bone formation.
Materials and Methods
Animal care. All experiments were conducted in compliance with institutional guidelines established by the 
Chancellor’s Animal Research Committee of the Office for Protection of Research Subjects at the University of 
California, Los Angeles (UCLA) and the UCLA Office of Animal Research Oversight. All experimental protocols 
were approved by the UCLA Animal Research Committee (Approval #2008–073 and #2003–093). A total of 102 
male Sprague Dawley rats at age of 8–12 weeks were purchased from Charles River. All animals were cared in 
compliance with Guidelines for the Care and Use of Laboratory Animal of the National Institutes of Health. Rats 
were housed at 2 animals per cage on a 12 hours light/dark cycle with a temperature and humidity-controlled 
room. All animals were fed standard Teklad Rodent Diets, and each of them had ad libitum access to water and 
food.
Mandibular defect model. The critical-size 5 × 5 mm mandibular defects were created in rats by the sur-
gical procedures as previously developed40. Briefly, the rats were subjected to general anesthesia with isoflurane 
gas, shaved on the ventral surface of mandible, and subsequently prepped and draped in a sterile manner. An 
incision overlying and parallel to the left mandible was made using a #15 blade. The inferior border of the man-
dible was then identified underneath the subcutaneous tissues. After isolating the pterygomasseteric sling with 
an electrocautery, the lingual and buccal surfaces of the mandibular body were exposed with further supraperi-
osteal lifting of the musculature. A 1-mm high-speed cutting burr (3,000 RPM) was then used to drill a 5 × 5 mm 
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defect with constant copious irrigation. An equivalent size of apatite-coated PLGA scaffold loaded with drugs 
(BMP2 purchased from R&D system, MN and GenScript, NJ) was instantly placed onto the mandibular defect 
using a resorbable suture, followed by a skin closure with non-resorbable suture. All rats after surgery were 
allowed to recover from anesthesia on warm sheets and then transported to the vivarium for postoperative care. 
Postoperatively, all rats received analgesia via subcutaneous injections of buprenorphine (0.1 mg/kg) up to 3 days. 
6 rats per group were set up for implantation.
Micro-computerized tomography (µCT) scanning. Animals were euthanized after 8 weeks of 
post-operation. Left hemi-mandible tissues were collected and instantly fixed in 4% formaldehyde with gentle 
shaking at room temperature for 48 hours. The fixed tissue samples were then rinsed with PBS solution three 
times and stored in 70% ethanol prior to imaging using a high-resolution microCT machine (µCT SkyScan 1172; 
SkyScan, Kontich, Belgium) at 10 µm resolution, 57 kVp, 184 µA and 0.5 mm aluminum filtration. All images 
were visualized and reconstructed using Dolphin 3D software (Dolphin Imaging & Management Solutions, 
Chatsworth, CA). The volume and area of new bone were assessed using CTAn (SkyScan, Kontich, Belgium) and 
Image J software (NIH), respectively. Bone-specific analysis included: new bone area/original defect area (% area) 
and new bone volume (BV, mm3), trabecular number (Tb.N, mm−1).
Histological, immunohistochemical and immunofluorescence analyses. The mandibular 
implants were extracted from sacrificed rats at week 1 postoperatively, and their volume and weight were meas-
ured immediately. For further histological and immunohistochemical analysis, the extracted mandible tissues 
from 1 weeks and 8 weeks post-operation were fixed with 10% formalin over 2 days. Subsequently, the fixed 
mandible tissues were decalcified by immersing them into 10% ethylenediaminetetraacetic acid (EDTA) solution 
with gentle shaking for two weeks, embedded in paraffin and sliced into 5 µm thickness of sections. The tissue 
sections were then deparaffinized with xylene (Sigma), hydrated in a gradient of ethanol and stained with hema-
toxylin and eosin (H&E) solution. The deparaffinized sections were further stained with 0.1% Picrosirius red 
solution (Polysciences, Inc., PA) for detection of collagen expression and were visualized under polarizing light 
microscope. Masson’s trichrome staining (Sigma) and tartrate-resistant acid phosphatase (TRAP) kit (Sigma) 
were adopted to detect new bone formation marked with light blue color, and osteoclast cell labeled with purple 
color respectively. In addition to histological staining, the tissue sections were also subjected to the immunohis-
tochemical analysis. The deparaffinized sections underwent citric acid antigen retrieval, were incubated with the 
primary antibodies (Santa Cruz) of anti-Trib3, PPARγ, NF-kB p65 (phospho), Runx-2, or OCN and stained by 
HRP/DAB detection kit (Abcam, MA) following the manufacturer’s instructions. The sections were also coun-
terstained with Mayers’s Hematoxylin (Abcam), and visualized under microscope. At 7 days postoperatively, the 
fixed tissue sections additionally underwent the immunofluorescence staining on CD68 expression by sequential 
incubation with primary antibodies of anti-CD68 and fluorochrome-conjugated secondary antibody along with 
DAPI staining for distinguishing cell nucleic acid. Each immunofluorescence image was further quantified by 
image J software (NIH).
Cell culture and transduction. Human bone marrow mesenchymal stem cells (hBMSCs) (n = 2 patients) 
purchased from Lonza (Vancouver, Canada), were amplified in human MesenCult™ proliferation medium 
(STEMCELL Technologies, Vancouver) to passage 2 for experiments. Mouse bone marrow stromal cells (mBM-
SCs, ATCC, VA), RAW264.7, NIH3T3, and C2C12 cells were proliferated under the growth medium (Invitrogen, 
CA) containing Low Glucose Dulbecco’s Modified Eagle Medium (LDMEM) and 10% fetal bovine serum (FBS). 
siRNA vectors targeting Trib3 or control (Santa Cruz Biotechnology, Inc., CA) were transduced to hBMSCs fol-
lowing the manufacturer’s protocols. In general, siRNAs at a concentration of 10 nM was transfected into cells at 
70% confluence on the 12-well cell culture plate by using Lipofectamine RNAiMAX (Invitrogen).
Alkaline phosphatase (ALP) activity, Alizarin red staining, Adipored assay and Oil red stain-
ing. To measure the degree of osteogenesis, the transduced hBMSCs on the 12-well cell culture plate were 
grown in the culture medium until approximately 100% confluence, and then the growth medium was replaced 
with osteogenic medium (Sigma, MO) containing 10 mM β-glycerophosphate, 50 µg/mL L-ascorbic acid, and 
100 nM dexamethasone, supplemented with and without phenamil (20 μM) (Sigma) and/or BMP-2 (100 ng/ml) 
(R&D System, MN). At day 3 of osteoinduction, the cells were fixed with 10% formalin (Sigma), stained with 
ALP colorimetric assay kit (Sigma) containing Nitro Blue tetrazolium, 5-Bromo-4-chloro-3-indoxylphosphate 
and AP buffer (100 mM Tris pH 8.5, 100 mM NaCl, 50 mM MgCl2), and imaged with Olympus BX 51 microscope 
(Japan). To further assess ALP activity, the cells were digested in 0.2% NP-40 lysis buffer (Life technologies, CA), 
subsequently incubated in the buffer containing p-nitrophenol phosphate substrate (Sigma), and measured of 
the absorbance at 405 nm using a multi-plate reader. Each measurement was finally standardized with total DNA 
content detected by PicoGreen dsDNA Assay (Life technologies). Alizarin red staining was performed to detect 
calcium deposition of cells after 2 weeks of osteogenic induction. The fixed cells with 10% formalin, were then 
stained with 2% alizarin red solution (Sigma) for 5 mins, and visualized with an Olympus BX 51 microscope. The 
stained cells were further quantitatively analyzed through dissolving the stained cells in 10% (v/v) acetic acid 
followed by measurement of the absorbance at 405 nm.
To analyze adipogenic differentiation, the transduced cells in 12-well plate at approximately 100% confluence 
were incubated in human MesenCult™ adipogenic medium (Lonza). Intracellular lipid accumulation within the 
differentiated adipocytes was assessed after 1 week of post-induction using the Adipored kit (Lonza) by absorb-
ance at 572 nm. For visualization of extracellular lipid expression, the cells at week 2 post-induction were stained 
with Oil Red O solution (Sigma) for 15 mins and were imaged with the microscope.
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RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA 
extraction from experimental cells was conducted using Trizol reagent (Life Technologies) and RNeasy Mini kit 
(Qiagen, CA) following the manufacture’s protocol. 500 ng aliquot of RNA for each sample was used to synthesize 
complementary DNA via a SuperScript III First-Strand Synthesis System (Life Technologies) according to the 
manufacturer’s instructions. Quantitative real-time PCR analysis was carried out using a 20 µL of SYBR Green 
reaction system in a LightCycler 480 PCR instrument (Roche, IN). GAPDH expression level was measured to 
normalize the expression level of each target gene. The sequences of each primer were listed in Supplementary 
Table 1.
Luciferase Assay. pNF-κB luciferase reporter assay was conducted following the manufacturer’s instruc-
tions. In brief, when the RAW264.7 cells on a 24-well cell culture plate reached approximately 70% confluence, 
they were co-transfected with pNF-κB and control plasmids (Promega, WI) using lipofectamine 2000 (Life 
Technologies). After 6 hours of transfection, the medium was replaced with cell growth medium supplemented 
with or without phenamil (20 μM) and/or BMP-2 (500 ng/mL). After extra 48 hours of treatment, luciferase activi-
ties of cells were measured by a dual luciferase reporter system (Promega), followed by normalization with Renilla 
internal control.
Western-blot assay. The western blot assay was performed according to the protocol previously estab-
lished15. Briefly, the cells were lysed in 0.2% NP-40 lysis buffer (Life technology), followed by the measurement 
of protein concentration using a bicinchoninic acid protein assay (Thermo Scientific, IL). The protein lysates of 
cells were then separated by Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE), blotted 
onto Immobilon polyvinyl difluoride (PVDF) membrane (Millipore, Billerica, MA), and incubated in the pri-
mary antibodies containing anti-Trb3 (Santa Cruz), anti-PPARγ (Santa Cruz), anti-Smurf1, anti-pSmad1/5/8 
(Santa Cruz), anti-NF-kB p65 (phospho) or anti-GAPDH (Santa Cruz). The membranes were further incubated 
in Horseradish Peroxidase (HRP)-conjugated secondary antibody (Millipore, MA), subsequently visualized with 
chemiluminescent HRP (Denville Scientific, NJ).
Co-culture of cells. Transwell Permeable Supports (3 μm porous) (Corning, NY) were applied to parac-
rine non-contact cell co-cultures following the manufacturer’s guidance. Briefly, the RAW264.7 cells and growth 
medium were added in the 12-well cell culture plate, subsequently Transwell support was inserted into each well 
onto which BMSCs and growth mediums were added. After 24 hours of co-culture, the growth medium was 
replaced with low serum (2% FBS) culture medium in the presence or absence of BMP-2 (500 ng/ml) and/or 
phenamil (20 μM). Over 7 days of in-vitro culture, the BMSCs growing in the Transwell support under osteogenic 
medium were stained by ALP assay. In addition, the mono-cultured medium only in RAW264.7 cells at day 3 
was collected for the examination of inflammatory cytokines secretion through a multi-analyte ELISArray kit 
(GIAGEN, Hilden, Germany) according to manufacturer’s instructions.
Scaffold fabrication. The apatite-coated PLGA scaffold was synthesized through the process of solvent cast-
ing and particulate leaching methodology as previously established15. In general, PLGA/Chloroform mixed solu-
tion was blended with 200–300 µm diameter of sucrose to form a porosity of approximate 92% (volume fraction), 
compressed into a Teflon mold and freeze-dried overnight at −110 °C and 100 mTorr (SP Industries, Inc., PA). 
Subsequently, the scaffolds were plunged in double-distilled (dd) H2O to remove sucrose and then sterilized in 
70% ethanol up to 30 mins, followed by several rinses in sterile ddH2O. And then the dried scaffold sheets were 
sliced into small plates at the size of 5 × 5 × 2 mm. Finally, the PLGA scaffold plate was coated an apatite layer 
through incubating it in simulated body fluid (SBF): The scaffold was first subjected to glow discharge argon 
plasma etching (Harrick Scientific, Pleasantville, NY); The etched scaffold was then incubated in SBF1 formu-
lated with the mixture of CaCl2, MgCl2 · 6H2O, NaHCO3, K2HPO4 · 3H2O, Na2SO4, KCl and NaCl for 24 hours and 
subsequently in SBF2 with the mixture of CaCl2, K2HPO4 · 3H2O, KCl and NaCl for another 24 hours at 37 °C.
Statistical analysis. Statistical analysis in the studies was performed by one-way analysis of variance 
(ANOVA) with the Tukey’s post hoc test. The data were presented as means ± SD. P-value < 0.05 was considered 
statistically significant.
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